Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement
2025-07-22 09:02:07 ET
Lyell Immunopharma ( LYEL ) has made significant progress with respect to its CD19/CD20 CAR-T cell therapy targeting patients with aggressive 3rd-line + Large B-Cell Lymphoma [LBCL]. The reason why is because it had been reported that these specific patients in the 3rd-line setting, given autologous LYL314 not only achieved high response rates but did so for an extended period of time. However, this is not my only reasoning for placing a "Hold" rating on this stock. It is because it already held an end-of-phase 1 [EOP1] meeting with the FDA and received feedback about being able to initiate a phase 3 program for this candidate....
Read the full article on Seeking Alpha
For further details see:
Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement
NASDAQ: LYEL
LYEL Trading
-2.13% G/L:
$24.37 Last:
40,301 Volume:
$24.69 Open:
